Movement Disorders

Here's some of what is coming soon to NeurologyLive® this week.

Neurology News Network. for the week ending October 11, 2025. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 10, 2025.

The associate professor and clinician-scientist at the University of Toronto spoke to the current understanding of protein waste clearance in neurodegeneration. [WATCH TIME: 4 minutes]

New data reveals bemdaneprocel, an innovative cell therapy for Parkinson disease, shows promising safety and efficacy over 36 months, paving the way for future trials.

A new phase 2 trial explores probiotics' potential to alleviate depression and mood disorders in patients with Parkinson disease, linking gut health to mental well-being.

The neurologist at University of British Columbia discussed how abnormal brain plasticity influences Parkinson progression and highlighted the importance of integrating basic science with clinical care.

Results from the extension phase of the IB1001-203 study, presented as a late-breaker at MDS 2025, suggest N-acetyl-L-leucine prevented worsening of disease progression in patients with ataxia-telangiectasia.

New heatmap analysis reveals continuous apomorphine infusion significantly improves ON time and reduces OFF episodes in patients with Parkinson disease.

In the MOXIe open-label extension study presented at MDS 2025, omaveloxolone treatment was associated with no significant disease progression in bulbar function or upper limb coordination.

The chief of the Movement Disorders Division at Yale School of Medicine discusses the nuance around patient choice in Huntington disease testing and providing treatment regardless of confirmation. [WATCH TIME: 3 minutes]

The chief medical officer of Gain Therapeutics discusses the challenges that are unaddressed with currently available treatments for Parkinson, and how investigational treatments like GT-02287 might address those needs. [WATCH TIME: 3 minutes]

Valbenazine shows significant improvements in physical, social, and emotional outcomes for tardive dyskinesia patients, as revealed in a recent study.

Here's some of what is coming soon to NeurologyLive® this week.

New real-world data confirms the safety and tolerability of high-dose apomorphine infusion for advanced Parkinson's disease, enhancing treatment options.

A phase 2 study shows risvodetinib improves safety and symptoms in early Parkinson disease, suggesting potential as a disease-modifying therapy.

New research highlights ecopipam's effectiveness in reducing Tourette syndrome symptoms and relapse risk in children, offering a promising treatment alternative.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on tardive dyskinesia.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 3, 2025.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 26, 2025.

AbbVie’s application to the FDA for its selective dopamine D1/D5 receptor partial agonist is supported by data from the phase 3 TEMPO study program.

UniQure's AMT-130 shows promise in slowing Huntington disease progression, paving the way for a potential breakthrough treatment by 2026.

At the 2025 STARS Research & Education Conference, Lisa LaSalle, PhD, professor at California State University, Monterey Bay, highlighted risk factors and care interventions for stuttering in children.

Here's some of what is coming soon to NeurologyLive® this week.